Navigation Links
Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA

Ranbaxy Laboratories (RL) has received its first tentative approval from the US Food and drug administration ( FDA ) to manufacture // and market lamivudine tablets that can be used in combination with other anti - retroviral agents (ARVs) to treat patients with HIV infection.

The approval has come after a number of quality checks and inspections by some of the most stringent agencies in the world including the US FDA.All the other ARVs including the present lamivudine tablets are at present being manufactured by Ranbaxy itself in its state of the art laboratories.

The CEO of Ranbaxy Laboratories has said that the approval by the US FDA is a great achievement and a major step forward in making life saving ARV medicines available to more and more individuals suffering with AIDS in the developing countries and he also promised to make all efforts to obtain speedy approval for all the other ARVs being manufactured by Ranbaxy Laboratories.
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
6. Ranbaxy opens Drug discovery centre in Gurgaon
7. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
8. SRL Ranbaxy offers quicker bird flu diagnostic test
9. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
10. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
11. Ranbaxy Expands By Acquiring A Generic Company In Belgium
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: